INSIDE THIS ISSUE

- Benefit Drug List
- Protocol Update – GUBCV, GUBPV, GUCMV, UGUGEMCIS, GUPM, GUPMX, LYABVD, LYCVP, SCPAINSU
- Cancer Management Manual
- Pre-Printed Order Update
- Focus on – Financial Aids for Cancer Patients
- Cancer Drug Manual
- Supportive Care – Sufentanil for Incident Pain
- Provincial Systemic Therapy Program Policies
- Communities Oncology Network - Retirement of CON Vice President
- Library/Cancer Information Centre
- Continuing Education - American Society of Clinical Oncology Annual Meeting, International Society of Oncology Pharmacy Practitioners Symposium

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BENEFIT DRUG LIST

The current Benefit Drug List and Class II forms are available on the website www.bccancer.bc.ca.

PROTOCOL UPDATE

Protocols by Drugs Index A cross-referenced index lists the BC Cancer Agency benefit drugs with their corresponding protocols. This index can be obtained via H-drive at regional cancer centres or Fax-back as listed at the end of the Update.

Protocol codes for treatments requiring "Undesignated Indication" approval prior to use are prefixed with the letter U.

- INDEX to BC Cancer Agency Protocol Summaries revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- GUBCV revised (clarification of CBC in Tests, contact physician changed): Therapy for transitional cell cancers using carboplatin-vinblastine
- GUBPV deleted: Therapy for transitional cell cancers using cisplatin-vinblastine
- GUCMV deleted: Therapy for transitional cell bladder cancers using cisplatin, methotrexate and vinblastine
- UGUGEMCIS revised (renal clearance added to eligibility and dose modifications): Palliative therapy for urothelial carcinoma using cisplatin and gemcitabine
- GUPM revised (eligibility): Therapy for hormone-resistant metastatic carcinoma of the prostate using mitomycin monotherapy
- GUPMX revised (eligibility): Palliative therapy for hormone refractory prostate cancer using mitoxantrone and prednisone
- LYABVD revised (dose reductions added for patients on NCIC CTG HD 7 protocol): Treatment of Hodgkin’s disease with doxorubicin, bleomycin, vinblastine, and dacarbazine
- LYCVP revised (ANC changed in Dose Modifications): Advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone
- SCPAINSU new: Incident pain therapy using sufentanil via sublingual route

Protocols are available on the BC Cancer Agency website www.bccancer.bc.ca/ccp/.

CANCER MANAGEMENT MANUAL

The Cancer Management Manual is available on BC Cancer Agency website www.bccancer.bc.ca/cmm/.
PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BC Cancer Agency protocol summaries. The BC Cancer Agency Vancouver Centre has prepared chemotherapy pre-printed orders, which can be used as a guide for reference. An index to the orders can be obtained by Fax-back.

FOCUS ON

Financial Aids for Cancer Patients

The Emergency Aid program for symptom control medications and the BC Palliative Care Benefit program are the two programs that may provide financial aid to cancer patients.

The Emergency Aid (EA) program is a joint partnership between the BC Cancer Agency (BCCA) and the Canadian Cancer Society (CCS), BC and Yukon division. This program was established in 1999 to assist cancer patients with the cost of symptom management medications. CCS determines the patient’s financial eligibility. BCCA provides funding and identifies eligible medications.

To be eligible for this program, patients must be:
- registered with a cancer diagnosis with the BC Cancer Registry
- under 65 years of age
- not receiving support from Pharmacare
- not receiving other government health support (e.g. Veteran Affairs, First Nation Bands, Department of Social Development and Economic Security or other insurance sources)

CCS will review the eligibility and financial status to determine if the patient qualifies for aid from this program. Individual hospital’s patient and family counselling department can act as a liaison and contact CCS on behalf of the patient. Once a patient has been accepted into the program:
- a letter of notification is sent to the pharmacy of the patient’s choice and to the BCCA-EA office
- patients take their prescriptions to the designated pharmacy, and pay only the pre-determined proportion
- only medications listed on the approved BCCA symptom control medications list will be covered
- reimbursement is made to the dispensing community pharmacy; there is no direct reimbursement to the patient and no retroactive payment.
- coverage is given for a one-year period, after which the patient must be reassessed.

The BC Palliative Care Benefits Program is funded and administered by the Regional Programs Division of the Ministry of Health. Established in February 2001, this program supports and enables individuals in the end-stage of any life-threatening illness or disease to remain at home by covering the cost of medication, medical supplies and equipment — all at no charge to the patient.

To be eligible, patients must be:
- BC residents covered under the Medical Service Plan
- diagnosed with a life-threatening disease or illness with a life expectancy of up to six months

Palliative Care Benefits coverage continues as long as the patient is diagnosed as requiring palliative care. The patient’s physician must certify that the individual meets the criteria for Palliative Care Benefits coverage, therefore the physician is responsible for registering eligible individuals.

For coverage of medication costs, the physician submits an application form directly to Pharmacare. Once the application is processed and information has been entered into the PharmaNet system, the patient’s prescription can be filled at their local community pharmacy. Only medications listed in the current BC Palliative Care Drug Formulary are covered. These include medications prescribed for pain and symptom control, medications to improve quality of life and selected over-the-counter (OTC) medications that may be required to supplement the prescription drugs. A prescription is required for the OTC drugs to ensure payment through PharmaNet. The plan does not cover vitamins, herbals, nutritional supplements, or medical marijuana.

For coverage of medical supplies and equipment, the physician must send a copy of the application form to the local health authority. A home care nurse or a nurse from the palliative care program will then contact the patient and arrange for a home visit to determine which medical supplies and equipment are needed. Eligible medical supplies and equipment are listed in the BC Palliative Care
Benefits package. These do not include ongoing diabetic supplies or ostomy supplies, which are already covered by Pharmacare.

For more information on the Emergency Aid program, you can contact:
- regional Canadian Cancer Society office in your community or call the Cancer Information Service line 1-888-939-3333
- Francis Hu, CON pharmacist, BC Cancer Agency, 1-800-663-3333 local 2515.

For more information on the BC Palliative Care Benefits Program, you can contact:
- BC Ministry of Health Information line 1-800-465-4911 or (250) 952-1742.

Dawn Annable
Pharmacy CON Educator
BC Cancer Agency-Fraser Valley Centre

The Cancer Drug Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/cdm/.

**SUPPORTIVE CARE**

**Sufentanil for Incident Pain** Incident pain or pain with movement in palliative care patients has a rapid onset and is often intense but transient in nature. The onset and duration of action of oral analgesics are usually too slow and long lasting for the management of incident pain, leading to inadequate pain control and unwanted adverse effects.

Sufentanil belongs to a class of fentanyl-related opioids which are better absorbed sublingually than morphine. Sublingual administration of sufentanil has the advantage of rapid absorption and increased bioavailability. Compared to fentanyl, sufentanil is nearly ten times more potent per volume and can be given sublingually in volumes of less than 1 mL. The onset of action is about 3 to 5 minutes and the duration of analgesia may last for 10-25 minutes.

The usual dose is 25 mcg (0.5 mL) every 5 minutes as needed, up to three doses per episode of pain. Patients should be monitored for sedation, increase or decrease in blood pressure and respiratory depression. See the SCPAINSU protocol for more details on the dosing regimen and monitoring parameters.
time basis to further develop educational programs for the BC Cancer Agency.
We want to wish Jack well in his new life and we hope he will have every opportunity to enjoy his recreational activities as well as his renewed commitment to education.

Susan O’Reilly, MB FRCPC
Provincial Systemic Program Leader

The interim contacts for CON related issues are: Jaya Venkatesh, Business Affairs Coordinator, Provincial Systemic Therapy Program at 1-800-663-3333 local 2732 or Dorothy Gifford, CON Secretary 1-800-663-3333 local 2744.

WEBSITE UPDATE

Improved Website Access As part of an ongoing Extranet project, the BC Cancer Agency website is being enhanced with the new Microsoft Content Management Server. This will allow faster access to the information posted on the website, including the Cancer Management Manual, Cancer Chemotherapy Protocols, and the Cancer Drug Manual, and patient information.

LIBRARY/CANCER INFORMATION CENTRE

Unconventional Cancer Therapies Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/uct/. The manual consists of 46 short monographs on the more commonly used unconventional cancer therapies (e.g., Essiac, vitamins, teas, shark cartilage) and includes tips for the patient and family on how unconventional therapies can be evaluated. For each therapy the manual provides proponent/advocate claims, as well as evidence-based evaluation/critique quotations from the literature.

CONTINUING EDUCATION

The American Society of Clinical Oncology (ASCO) 38th Annual Meeting will be held in Orlando, Florida, on May 18-21, 2002. Information can be found on the ASCO website at www.ASCO.org.

International Society of Oncology Pharmacy Practitioners (ISOPP) VIII Symposium will be held on 7-11 May, 2002, at the Fairmont Hotel (Vancouver) in Vancouver, BC. The conference has a wide ranging program for the oncology pharmacist, from setting up a chemotherapy service to pharmacogenomics, drug and disease updates, molecular biology, advances in safe handling of antineoplastics, and symptom management issues.

The keynote speaker will be Dr. David Suzuki, internationally renowned television personality, geneticist, and environmental activist. Other speakers include Howard Pai, Dianne Kapty, Kimberly Kuik, Robin O’Brien, Lynne Nakashima, and Suzanne Taylor of the BC Cancer Agency Systemic Therapy Program, and Dana Cole of the Prince George Regional Hospital.

For more information, visit the conference website at www.isopp.org or contact Jeff Barnett at jbarnett@bccancer.bc.ca or (250) 519-5519.

Editorial Review Board

Mário de Lemos, PharmD (Editor)
Sharon Allan, MD
Sandi Broughton, BA(Econ), MSc
Karen Janes, MSN
David Noble, BSc, BLS
Jaya Venkatesh, BCom, BA, MHA
Susan Walisser, BSc(Pharm)
Gigi Concon (Secretary)
| Centre for the Southern Interior (CCSI) | (250) 712-3900 | Toll-Free 1-(888)-563-7773 |
| Fraser Valley Centre (FVCC) | (604)-930-2098 | Toll-Free 1-(800)-523-2885 |
| Vancouver Centre (VCC) | (604)-877-6000 | Toll-Free 1-(800)-663-3333 |
| Vancouver Island Centre (VICC) | (250) 519-5500 | Toll-Free 1-(800)-670-3322 |

**BC CANCER AGENCY SYSTEMIC THERAPY UPDATE FAX REQUEST FORM**

**FAX (604) 877-0585**

**bulletin@bccancer.bc.ca**

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247

OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

- [ ] E-mail (Word 6.0)
- [ ] Fax

**UPDATES** Please [ ] Fax-Back information below:

- [ ] All items
- [ ] Pre-Printed Orders:
  - [ ] Index: Pre-Printed Orders
- [ ] Protocol Summaries: (also available on our website www.bccancer.bc.ca)
  - [ ] GUBCV
  - [ ] GUCMV
  - [ ] GUPM
  - [ ] LYABVD
  - [ ] SCPAINSU
- [ ] Index: Protocol Summaries (current month)
- [ ] Reimbursement (also available on our website www.bccancer.bc.ca)
  - [ ] Benefit Drug List (01 March 2002)
  - [ ] Class 2 Form (01 February 2002)
  - [ ] Filgrastim Usage Form (01 June 2001)
  - [ ] Undesignated Indication Form (November 2001)
- [ ] Systemic Therapy Update Index (also available on our website www.bccancer.bc.ca)
  - [ ] Jan-Dec 2000
  - [ ] Jan-Dec 2001
<table>
<thead>
<tr>
<th>BULLETIN UPDATES</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Printed Orders</td>
<td>H:\everyone\systemic\chemo\Orders\VCC</td>
</tr>
<tr>
<td>Index of Pre-Printed Orders</td>
<td>Index.doc</td>
</tr>
<tr>
<td>Protocol Summaries</td>
<td>H:\everyone\systemic\chemo\Protocol\“tumour site”</td>
</tr>
<tr>
<td>Index of Protocol Summaries</td>
<td>Index_NT or Index_W6</td>
</tr>
<tr>
<td>GUBCV</td>
<td></td>
</tr>
<tr>
<td>GUBPV</td>
<td></td>
</tr>
<tr>
<td>GUCMV</td>
<td>UUGEMCIS</td>
</tr>
<tr>
<td>GUPM</td>
<td>GUPMX</td>
</tr>
<tr>
<td>LYABVD</td>
<td>LYCVP</td>
</tr>
<tr>
<td>SCPAISU</td>
<td></td>
</tr>
<tr>
<td>Reimbursement</td>
<td>H:\everyone\systemic\chemo\Reimburs</td>
</tr>
<tr>
<td>Benefit Drug List (1 March 2001)</td>
<td>BenefitList.doc</td>
</tr>
<tr>
<td>Class 2 Form (1 February 2001)</td>
<td>Class2.doc</td>
</tr>
<tr>
<td>Filgrastim Usage Form (1 June 2001)</td>
<td>GCSF_form.doc</td>
</tr>
<tr>
<td>Undesignated Indication Form</td>
<td>Undesig.doc</td>
</tr>
<tr>
<td>(November 2001)</td>
<td></td>
</tr>
</tbody>
</table>

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca